Endocr Relat Cancer. 2006 Jun;13(2):583-92.
Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.
Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE.
Endocr Relat Cancer
Endocr Relat Cancer. 2006 Jun;13(2):583-92.
Testosterone treatment after prostate cancer
Department of Urology, Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio 44106, USA.
A history of prostate cancer has been an absolute contraindication for testosterone supplementation. We studied a cohort of hypogonadal patients treated with radical retropubic prostatectomy (RRP) for organ confined prostate cancer to determine if testosterone replacement therapy (TRT) could be efficacious and administered safely without causing recurrent prostate tumor.
Estrogen and Breast Cancer: Women suffer estrogen deprivation due to a medical community that disregards a safe alternative.
In September 2012, a jury in Salt Lake City, Utah awarded a breast cancer survivor $5.1 million in a court case against the pharmaceutical company, Wyeth (also known as Pfizer), alleging that the use of Premarin-Provera (Prempro) was responsible for the development of her breast cancer.1 This is one of many lawsuits against Wyeth, since the Women’s Health Initiative trial (WHI) was published in 2002. The general matter for this case is whether Wyeth withheld data and failed to inform the public concerning the risk of breast cancer with the use of the synthetic hormones, Prempro. There have been over 10,000 cases filed against Wyeth, which has paid $896 million to resolve over 6,000 lawsuits. Furthermore, they have set aside an additional $330 million to resolve the remaining lawsuits.
Metabolic syndrome after menopause and the role of hormones.
Department of Obstetrics & Gynecology, Columbia University College of Physicians & Surgeons, New York, NY 10032, United States. email@example.com
Menopausal Transition Linked to New Onset of Depressive Symptoms
Reuters Health Information 2006. © 2006 Reuters Ltd.
Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
Low Estradiol Levels and Progression of Heart Disease
The Journal of Clinical Endocrinology & Metabolism Vol. 93, No. 1 131-138
Copyright © 2008 by The Endocrine Society
Relationship between Serum Levels of Sex Hormones and Progression of Subclinical Atherosclerosis in Postmenopausal Women
Roksana Karim, Howard N. Hodis, Frank Z. Stanczyk, Rogerio A. Lobo and Wendy J. Mack
Inflammation and Breast Cancer mortality
In a study conducted by Cornelia Ulrich, Ph.D. and colleagues from the Cancer Prevention Program at the Fred Hutchinson Cancer Research Center in Seattle, elevated levels of two proteins in the blood – C-reactive protein (CRP) and serum amyloid A (SAA) – were found to be associated with overall survival rates in patients with breast cancer. The study involved 734 breast cancer patients, with data drawn from the Health, Eating, Activity and Lifestyle (HEAL) study, a multi-ethnic National Institutes of Health-funded prospective group of women diagnosed with Stage 0 to Stage IIIa breast cancer. Measurements of the CRP and SAA proteins were taken 31 months after initial diagnosis.
The researchers found that those women with the top-third highest levels of SAA were three times more likely to die from their disease within the following seven years compared to the group of patients in the lowest third. They also found a two-fold increased risk of death in women with the top-third highest levels of CRP.
Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells
Mol Cell Endocrinol. 2010 May 14;320(1-2):162-70. Epub 2010 Feb 6.
Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V, Maggiolini M.
Dipartimento Farmaco-Biologico, Università della Calabria, Rende (CS), Italy.
Timing of Estrogen Therapy Determines Anti-Stroke Benefit
Information from Industry
NEW YORK (Reuters Health) Mar 26 – The timing of estrogen therapy after menopause appears to play a key role in determining whether this intervention will protect against or facilitate damage from a stroke, findings from an animal study suggest. This may help explain seemingly discordant findings from previous studies.